Mitogen-activated protein kinase kinase kinase
From Proteopedia
(Difference between revisions)
| Line 12: | Line 12: | ||
{{#tree:id=OrganizedByTopic|openlevels=0| | {{#tree:id=OrganizedByTopic|openlevels=0| | ||
| - | * MAP3K1 | + | * MAP3K1; Domains – kinase 10-307; SH3-binding 465-480; TOG 648-867 |
| - | **[[1uti]] - MAP3K1+GRB2-related adaptor protein 2 - mouse | + | **[[6nfy]], [[6nfz]] - hMAP3K1 kinase domain + cancer drug - human<br /> |
| + | **[[6ng0]] - hMAP3K1 kinase domain (mutant) + cancer drug <br /> | ||
| + | **[[6nyb]] - hMAP3K1 kinase domain (mutant) + B-raf + 14-3-3 protein ζ – Cryo EM<br /> | ||
| + | **[[6whb]] - hMAP3K1 TOG domain + cancer drug <br /> | ||
| + | |||
| + | **[[1uti]] - MAP3K1 SH3-binding domain +GRB2-related adaptor protein 2 - mouse | ||
*MAP3K2 | *MAP3K2 | ||
| - | **[[2cu1]] - hMAP3K2 PB1 domain (mutant) | + | **[[2cu1]] - hMAP3K2 PB1 domain (mutant) - NMR<br /> |
| - | **[[2o2v]], [[5uoj]] – hMAP3K2+ | + | **[[2o2v]], [[5uoj]] – hMAP3K2+hMAP3K<br /> |
**[[2npt]] - hMAP3K2 PHOX domain + hMAP2K5 PHOX domain | **[[2npt]] - hMAP3K2 PHOX domain + hMAP2K5 PHOX domain | ||
| Line 31: | Line 36: | ||
**[[2clq]] – hMAP3K5<br /> | **[[2clq]] – hMAP3K5<br /> | ||
| - | **[[4bf2]], [[4bhn]], [[4bib]], [[4bic]], [[4bid]], [[4bie]] - hMAP3K5 (mutant) + inhibitor<br /> | + | **[[6oyt]], [[6vre]], [[6xih]] - hMAP3K5 + inhibitor<br /> |
| + | **[[4bf2]], [[4bhn]], [[4bib]], [[4bic]], [[4bid]], [[4bie]], [[6e2m]], [[6e2n]], [[6e2o]], [[6oyw]] - hMAP3K5 (mutant) + inhibitor<br /> | ||
*MAP3K7 (TAK1) | *MAP3K7 (TAK1) | ||
| Line 46: | Line 52: | ||
**[[2rf0]] - hMAP3K10 SH3 domain - NMR | **[[2rf0]] - hMAP3K10 SH3 domain - NMR | ||
| - | *MAP3K14 | + | *MAP3K14 kinase domain 343-686 |
**[[4dn5]] - hMAP3K14 (mutant) + ATP-γ-S<br /> | **[[4dn5]] - hMAP3K14 (mutant) + ATP-γ-S<br /> | ||
| - | **[[4idt]], [[4idv]] - hMAP3K14 + inhibitor<br /> | + | **[[4idt]], [[4idv]], [[6wpp]] - hMAP3K14 + inhibitor<br /> |
| + | **[[6g4y]], [[6g4z]], [[6myn]] - mMAP3K14 + inhibitor<br /> | ||
| + | |||
| + | *MAP3K15 | ||
| + | |||
| + | **[[6v0m]] - hMAP3K15 residues 1241-1308<br /> | ||
| + | |||
| + | *MAP3K MLT | ||
| + | |||
| + | **[[6jut]], [[6juu]] - hMAP3K + inhibitor<br /> | ||
}} | }} | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Revision as of 07:30, 8 September 2020
| |||||||||||
3D Structures of Mitogen-activated protein kinase kinase kinase
Updated on 08-September-2020
References
- ↑ Ellinger-Ziegelbauer H, Brown K, Kelly K, Siebenlist U. Direct activation of the stress-activated protein kinase (SAPK) and extracellular signal-regulated protein kinase (ERK) pathways by an inducible mitogen-activated protein Kinase/ERK kinase kinase 3 (MEKK) derivative. J Biol Chem. 1997 Jan 31;272(5):2668-74. PMID:9006902
- ↑ Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, Yue W. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol. 2002 Feb;80(2):239-56. PMID:11897507

